Shane Schaffer

Shane Schaffer is the co-founder, Chairman, and CEO of Cingulate Therapeutics, a biopharmaceutical company in Kansas City, Kansas, currently in the Phase 3 clinical stage. This company specializes in developing next-generation pharmaceuticals, focusing on Attention Deficit/Hyperactivity Disorder (ADHD), anxiety disorders, and insomnia.

With a 25-year tenure in the pharmaceutical industry, he specializes in drug development and commercialization and is noted for his leadership and entrepreneurial drive in product launches and brand management. He completed his doctoral degree in Pharmacy at the University of Kansas in 1999, followed by a postdoctoral pharmaceutical industry fellowship at Rutgers University’s College of Pharmacy, where he worked with teams at Pfizer Worldwide Marketing and Morris Plains.

While with Pfizer Worldwide Marketing in New York, NY, he served as a Marketing Manager, where he developed pre-launch strategies and initiated the Global Communications Intranet to foster better communication between medical and marketing stakeholders. In Morris Plains, New Jersey, he was Project Manager and External Research Manager, leading advanced sales training and supervising Phase IV Medical Research.

Throughout his career, he has held several managerial positions at companies like Pfizer, Novartis, and Sanofi, proving himself to be a versatile leader who has developed and commercialized several billion-dollar brands. At Novartis, he managed the Ritalin® LA and Focalin™ segments from inception, leading to significant market achievements and high product awareness shortly after their launches. He has earned multiple awards for his strategic leadership.

After Novartis, he continued to achieve at Sanofi, driving successful initiatives and promotional campaigns for products such as Avapro and Avalide and managing promotions for Hyalgan, Eligard, and Arixtra, which significantly contributed to his receiving the Sanofi Star Award multiple times.

Following his time at Sanofi, he joined M|C Communications LLC in Boston as a consultant, where he developed business opportunities for numerous major pharmaceutical companies. In July 2009, he founded Sabre Scientific Solutions, LLC, providing consulting services to the pharmaceutical and biotechnology sectors, focusing on commercials, clinical operations, and product launches.

In 2013, his passion for improving ADHD and anxiety disorder treatments led him to establish Cingulate Therapeutics LLC, focusing on innovative drug-delivery technologies. The company recently partnered with Indegene to market its oral ADHD medication, CTx-1301 and plans to submit a new drug application to the FDA by mid-2025.

Beyond his professional endeavors, Shane Schaffer is actively involved with the Folds of Honor Charity, providing scholarships and educational support to children of fallen or disabled military personnel. His dedication extends from the pharmaceutical industry to significant philanthropic efforts, demonstrating his commitment to both innovation in healthcare and community support.